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Abstract 
Drug conjugation gives many advantages such as improved targeting, solubility and 
retention. How conjugated drugs interact with proteins is a key question to answer in 
targeted drug delivery. This not only includes the interaction with the target protein, but 
also includes the proteins that the drug carrier may encounter during drug trafficking. Folic 
acid (FA) is of wide interest as a targeting agent. It provides targeting effect towards the 
folate receptor (FR), a commonly overexpressed protein in breast cancer and ovarian 
cancer. Chapter one focused on developing a conjugated tighter binder towards the soluble 
form of folate receptor, folate binding protein (FBP). This strategy employed a PAMAM 
dendrimer conjugated folic acid; the dissociation constant was improved from 20 nM of 
free folic acid to 2 nM of the dendrimer conjugated folic acid. The folate binding protein 
is a minor serum protein and is known to aggregate upon binding to folic acid. This 
aggregation could pose risk factors for drug delivery vectors such as the folic acid 
conjugated iron oxide nanoparticles. In chapter two, folate binding protein was shown to 
aggregate to large iron oxide nanoparticles that are conjugated to folic acid, triggering the 
agglomeration cascade that could drastically change the size of these nanoparticles.  
Chapter three addresses a question that is important to sport medicine:  what leads 
to non-contact anterior cruciate ligament (ACL) failure? Our hypothesis was that before 
xi 
 
the ACL fracture, microdamage would have already been created by jumping and landing 
activities. In this chapter, paired cadaveric knees were collected and one of the pair was 
mechanically tested under submaximal loading to see to what extent the microdamage 
would be created. A hierarchical damage ranging from nanometer level to micrometer level 
were detected using various methods including atomic force microscopy (AFM), nanoIR, 
second harmonic generation (SHG) and confocal microscopy. These microdamages 
exhibits patterns that resemble the fractured ACL seen in the clinical patients.  
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Chapter I 
Enhanced Folate Binding Protein Avidity: a Two Step Process Mediated by 
Dendrimer Exosite Binding 
Introduction 
Polymer-ligand conjugates are designed to bind protein active sites for applications 
as drugs, imaging agents, and transport scaffolds.1-3 The polymer provides many potential 
advantages including increasing ligand solubility, enhancing the circulation time, and 
shielding the ligand from unwanted protein interactions. These strategies have been 
successfully implemented for mono-functional poly(ethyleneglycol) (PEG) polymers and 
translated into successful drugs in the clinic.4 In principle, polymer scaffolds can also be 
employed to improve ligand to protein binding.  However, the major strategy employed in 
this regard, multivalent display of the ligand, has failed to realize the theoretically 
achievable improvements in binding.5-6   
Vitamins are particularly attractive molecules for drug targeting since they are 
naturally occurring, often exhibit low toxicity and high stability in plasma and tissue, and 
are preferentially taken up by quickly replicating cancer cells.7 Substantial effort has been 
expended to develop polymer conjugates of vitamins for use in targeting and imaging 
cancer cells.  In particular, vitamin B9 or folic acid (FA) has received extensive attention 
in this regard, and seven molecular conjugates have advanced to clinical trials.7 Despite 
great promise, FA-conjugates have not yet advanced to clinic.  Polymer conjugates of FA 
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have also been extensively explored 
including multivalent display of the 
ligand to enhance total binding strength 
and/or selectivity to displays of FA 
receptors.8-9   
We now report a new strategy to 
achieve tight polymer-ligand conjugate 
binding to target proteins by exploiting polymer-protein interactions. The strategy employs 
substrate-triggered exosite binding of the protein and polymer surfaces. It is known that 
FA induces changes in the secondary structure of FBP upon binding, including the 
formation of new domains of –helix and –sheet and rearrangement of a loop near the 
entrance to the binding site.10 We show that after these structural changes have been 
triggered by binding, the generation five poly(amidoamine) (G5 PAMAM) dendrimer 
conjugated to the FA interacts with the protein surface.  This new exosite interaction results 
in strong binding of the ligand-dendrimer conjugate to FBP. The polymer-
conjugate/exosite binding strategy is potentially useful as it offers specificity of interaction 
based on the natural protein ligand. This strong, tight binding could be of substantial benefit 
for FA-conjugated imaging agents. Figure 1.1 illustrates the proposed binding mechanism 
with the induced –helix and –sheet highlighted. 
Folate binding protein (FBP) describes two membrane-bound isoforms of the 
protein: folate receptor alpha (FR-) and folate receptor beta (FR-β) that are linked to 
plasma cell membranes via glycosylphosphatidylinositol (GPI) anchors.11-12 There is also 
a secreted form, FR-γ, that lacks the GPI anchor.  All forms of the protein have molecular 
Figure 1.1  Synergistic exosite binding mechanism. 
The –helix and –sheet secondary structure 
formed upon FA binding is highlighted purple in the 
X-ray crystal structure below. 
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weights at around 30 kDa.   Soluble FBP, present at 1-2 nM concentration in human serum 
and other body fluids and 100 nM concentrations in milk,12-17 is believed to be a mixture 
of FR-γ and FR- that has undergone cleavage of the GPI anchor.  X-ray crystal structures 
of FA-bound FR- and FA-bound FR-β were recently reported.10, 18 In the studies reported 
here, we employed bovine FBP (bFBP) isolated from milk.  bFBP has overall >80% 
homology with human FR- (hFR-).  In particular, there is 100% homology for 21 key 
residues forming the FA binding pocket, which includes the –QSWRKERVL- section of 
the inner strand of the nascent –sheet that forms upon FA binding.  
Experimental Section 
Materials. PEG-FA conjugates (2k, 5k, 30k) were purchased from Nanocs Inc.  G5 
PAMAM dendrimer was purchased from Dendritech and purified to remove trailing 
generation and G5 oligomer impurities as previously reported.19 G5Ac-COG-FA1.0 (credit: 
Mallory A. van Dongen, Ananda Kumar Kanduluru, Philip S. Low)20 and G5Ac-FITC1.9-
FA4.4  (credit: Rachel L. Merzel, Casey A. Dougherty) were synthesized according to 
previously reported methods.21-22 All dendrimers used have the primary amine terminal 
groups acetylated (Ac) to avoid protonation in aqueous buffer.  Whey protein concentrate 
was purchased from Natural Foods Inc. and purified as briefly described below following 
previously reported methods.23 All other chemicals and materials were purchased from 
Sigma-Aldrich or Fischer Scientific and used as received. 
Extraction, Purification, and Activity of FBP 
A 200 mL bed volume of Sepharose 4B was activated by cyanogen bromide and 
subsequently conjugated to FA.  A pH 7.0 2% (w/v) whey protein solution was centrifuged 
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(20,000 g) for 20 minutes. The resulting supernatant was loaded on the FA affinity column. 
10 L of supernatant was run through the column prior to the onset of back-pressure.  
Unbound protein was washed away using 2 L of 1 M NaCl followed until the solution ran 
clear using at least 2L of nanopure water. 300 mL of 0.3 M acetic acid solution was used 
to flush the FBP off the column. The solution was collected by fractions. Fractions with 
90% FBP purity were combined and the pH was adjusted to 7.0 by the addition of 5.0 M 
NaOH.   
Fluorescence Measurements 
All fluorescence measurements were carried out on a Varian Cary Eclipse 
Fluorescence Spectrophotometer. A 58 nM folate binding protein solution was made in pH 
7.4 1x PBS. The temperature control was set at 22 °C.  Excitation wavelengths of 280 nm 
for tryptophan and 495nm for FITC were employed.  The slit widths were 8 nm for both 
excitation and emission monochromators.  In all cases, fluorescence measurements were 
taken after the solutions had reached an equilibrium value.  
Results and Discussion 
In previous surface plasmon resonance (SPR) studies of G5-FA/FBP binding, we 
discovered that G5-FAn (n = 1, 2 or various navg) bound essentially irreversibly to bFBP.
20, 
24 Using atomic force microscopy (AFM) force-pulling studies, we found that the most 
probable rupture forces were 83, 201, and 189 pN for G5-FA2.7, G5-FA4.7, and G5-FA7.2, 
respectively.25 Intriguingly, although the probability of interaction decreased with FA-
blocking, the force magnitude of the most probable rupture force increased from 189 to 
274 pN for G5-FA7.2.  The combination of the SPR and AFM force-pulling data is 
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consistent with a slow-onset, tight-binding (SOTB) FA/FBP binding mechanism where 
FA-binding induces significant structural change in the bFBP secondary structure, 
allowing a network of van der Waals interactions to form between the G5 PAMAM 
dendrimer surface and the bFBP surface. 20, 25 
The interaction between polymer backbones and proteins is considered to be the 
most important factor in polymer-based drug delivery and biodevice development.26 
Proteins have been shown to interact with polymers via a complex set of interactions that 
include generalised electrostatic,27 van der waals,28 and H-bonding29 interactions and more 
specific protein-polymer binding.30 These interactions have generally been studied in the 
context of protein adsoprtion onto surfaces as opposed to the triggered exosite binding 
described herein.  
To further explore the nature of these interactions, we have performed a series of 
solution-phase fluorescence quenching experiments taking advantage of the intrinsic 
fluorescence associated with the 11 tryptophan residues present in bFBP.  For these studies, 
Figure 1.2.  G5 PAMAM and PEG FA-conjugates employed in this study. 
 
G5Ac-COG-FA	
FA 
G5 PAMAM 
~5nM 
Dipeptide Linker 
(Asp, Lys) 
COG linker 
(cyclooct-1-yn-3-glycolic acid) 
G5Ac-FITC1.9-FA4.4	
FA G5 PAMAM 
PEG(30k)-FA,	n=671	
PEG(2k)-FA,	n=34	
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we employed the following FA-polymer conjugates: 1) FA stochastically conjugated to a 
terminal PAMAM amine group (Figure 1.2, G5Ac -FITC1.9-FA4.4). This provides a direct 
comparison to our initial SPR24 and force-pulling25 studies and other stochastic FA 
conjugations for G5 PAMAM reported in the literature;8, 31-34 2) A G5-FA conjugate 
containing precisely one FA molecule per G5 PAMAM polymer (G5Ac-COG-FA1.0). This 
eliminates any effects arising from multivalent FA interactions including bridging between 
two bFBP.  Recent SPR studies on G5Ac-COG-FA1.0 led to the proposed SOTB interaction 
for G5-FA/FBP binding;20 3) FA-PEG conjugates directly linked via a FA carboxylic acid 
to the terminal PEG amine.  The 30 kDA PEG (PEG30k-FA) was chosen to provide an 
equivalent MW to that of acetylated G5Ac PAMAM.  The 2 kDa PEG (PEG2k-FA) was 
chosen to provide a PEG conjugate with less steric bulk. 
Fluorescence Quenching of bFBP upon FA and FA-conjugate Binding 
Fluorescence quenching titration 
provides a high sensitivity method for 
studying biological processes due to its 
high sensitivity.35 However when 
employing this technique to make 
quantitative measurements, it is 
important to correct for inner filter 
effects (IFE) and dynamic quenching 
that can decrease the observed light 
Figure 1.3.  Modified Stern-Volmer fitting of 
tryptophan quenching curves after the conjugation.  
G5Ac,  PEG2k-COG-FA(mix) , PEG30k-FA, 
PEG2k-FA, G5Ac-FITC1.9-FA4.4, FA, 
G5Ac-COG-FA. 
The concentration of FBP in each case is 58 nM (pH 
7.4, 1x PBS solution). 
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intensity.36 At the submicromolar concentrations of 
titrant employed for these studies, IFE did not 
cause an observable effect in light intensity for any 
of the polymer conjugates. 
 
Titration of a 58 nM FBP solution with FA 
results in a roughly 50% quenching of the native 
tryptophan fluorescence (Figure 1.3).  This experiment was suggested by Dr. E Neil G 
Marsh. A comparison of the apo-FPB and FA-FBP X-ray structures indicates that the 
majority of the tryptophan residues do not change position upon FA binding.10 Notable 
exceptions are W171, which is located on the protein surface away from the FA binding 
site, and W102, which is located on the loop adjacent to the FA-binding site and plays a 
key role in FA binding and –sheet formation (Figure 1.4).  The distance between W102 
and the FA benzamide ring (5.1 Å, 15° angle) is consistent with parallel-displaced - 
stacking.10 Tryptophan W171 is also of particular interest as it -stacks with FA pteridine 
ring (3.7 Å, 15° angle). W64, 120 134, 138, and 140, all located along the FA binding site, 
are highlighted in green in Figure 1.4.  Titration with G5Ac-FITC1.9-FA4.4 resulted in a 
similar quenching level to that observed for free FA (Figure 1.3).  Surprisingly, titration 
with G5Ac-COG-FA1.0 resulted in roughly 80% fluorescence quenching and exhibits a 
steeper initial slope indicating a different stoichiometry of interaction. Treatment of FBP 
with free FA, followed by addition of acetylated G5 dendrimer (G5Ac), resulted in no 
additional fluorescence quenching. This result indicates that for the enhanced fluorescence 
Figure 1.4.  Locations of tryptophans 
(green and red) and bound FA (yellow) 
in hFR-. W171 & W102 (bottom) are 
highlighted in red. 
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quenching to occur the dendrimer must be conjugated to FA.  Thus, synergistic binding 
requires both FA-induced FBP structural change and FA conjugation to the dendrimer.   
In order to explore the role of polymer in the binding process, studies were carried 
out with PEG30k-FA and PEG2k-FA.  As illustrated in Figure 1.3, titration of FBP with 
PEG30k-FA or PEG2k-COG-FA resulted in only about 20% fluorescence quenching and had 
not yet reached saturation by 120 nM of added conjugate.  This data demonstrates the 
equilibrium binding shift expected for conjugates that have steric constraints to achieving 
FA-FBP binding.  The PEG2k-FA exhibits similar quenching to free FA whereas PEG30k-
FA requires a roughly 2-fold greater concentration to achieve saturated binding.  PEG2k-
COG-FA binds less effectively than PEG2k-FA suggesting that the COG linker is 
increasing steric constraints in this case.  This is an important control as it demonstrates 
that the presence of the triazole ring/tryptophan interactions do not induce the large amount 
of quenching observed for G5Ac-COG-FA1.0.  The PEG-FA conjugates demonstrate the 
typical result of polymer conjugation to a protein binding substrate, namely, equivalent 
binding or reduced binding caused by steric constraints.  The results provide a distinct 
contrast to the binding interaction of G5Ac-COG-FA1.0 with FBP where a dramatic increase 
in binding constant20 and fluorescence quenching is observed.     
The fluorescence quenching curves were fit to the modified Stern-Volmer equation 
to assess binding avidity of polymer conjugates to FBP. 37  
 
 
0
[Q]
1
[Q]
a
D
fI
I K
 

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I is the intensity of the fluorophore, fa is the fraction of accessible fluorophores, KD is the 
dissociation constant, and [Q] is the free titrant concentration calculated from a quadratic 
equation (Scheme S1).38 A static quenching effect from binding was observed from the 
fitting. The plots (Figure 1.3) yield KD = 27.9 ± 3.3 nM for FBP binding FA, similar to the 
literature value of 20 nM,39 whereas the G5Ac-COG-FA1.0 conjugate bound FBP with KD = 
2.43 ± 0.17 nM, roughly ten-fold more tightly than FA. The PEG30k-FA isotherm bound 
with KD = 51.4 ± 6.4 nM, indicating that the polymer plays a relatively small role in 
modulating the binding avidity to FBP. G5Ac-COG-FA1.0 quenches a larger fraction of 
accessible fluorophores (fa = 87 ± 1%) as compared to FA (fa = 67 ± 3%) or PEG30k-FA (fa 
= 66 ± 4%). This is presumably an indication of the large conformational change induced 
by the dendrimer binding to the exosite on the protein surface.  
The binding avidity comparison of FA/FBP and G5Ac-COG-FA1.0/FBP was tested 
by first saturating FBP with 14 equiv FA (Figure 1.5).  The subsequent addition of 1.4 
Figure 1.5.  Tight binding of G5Ac-COG-FA1.0 to FBP. A) Fluorescence quenching of 58 nM FBP in the 
presence of 800nM FA B) 80 nM G5Ac-COG-FA1.0 binds to FBP, displacing FA, in the presence of 
excess FA.  C) The presence of an additional 800nM excess FA does not displace G5Ac-COG-FA1.0.  
The FBP concentration is 58 nM (pH 7.4, 1x PBS solution). 
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equiv G5Ac-COG-FA1.0 induced 
additional quenching to the 80% level 
previously observed for G5Ac-COG-
FA1.0 alone.  We interpreted this as 
essentially complete displacement of 
FA by G5Ac-COG-FA1.0 in the FBP 
binding pocket by the 10-fold 
stronger binder.  The addition of 
another 14 equivalents of FA, to give 
a 28-fold excess of FA over 
dendrimer conjugate, failed to 
displace G5Ac-COG-FA1.0 from FBP.  
Thus, the COG linked conjugation of 
FA to G5 PAMAM successfully 
created a stronger binder to the FBP 
protein that acts via dendrimer 
binding to the FBP surface outside of 
the FA binding pocket, i.e. an exosite binding interaction.  As illustrated in Figure 1.1, the 
nearest region showing extensive FBP surface structural change is the –sheet region and 
this appears to be likeliest dendrimer/protein binding site. However, the 30 kDa dendrimer 
is similar in size to FBP and binding to the induced -helix or other protein surface sites 
cannot be ruled out.  For this system, a synergistic interaction between the dendrimer and 
the protein affords tight binding. 
Figure 1.6 Tryptophan fluorescence from FBP a) 
Tryptophan fluorescence from FBP in the presence of 
folic acid (FA) and G5Ac-FITC1.9-FA4.4 conjugate, ex: 
280nm b) FITC fluorescence from G5Ac -FITC1.9-FA4.4 
in the presence of folic acid (FA) and FBP, ex: 495nm. 
The concentration of FBP in each case was 58 nM (pH 
7.4, 1x PBS solution). 
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We also explored competitive binding of FA/FBP and G5Ac-FITC1.9-FA4.4/FBP.  In 
this instance, the tryptophan fluorescence and FITC fluorescence can be observed in 
separate channels.  Both tryptophan and FITC fluorescence are quenched upon mixing 100 
nM G5Ac-FITC1.9-FA4.4 with 58nM FBP (Figure 1.6, red curves). Upon addition of 100 nM 
FA, a small amount of additional quenching is observed consistent with the initial sub-
stoichiometric treatment of FBP with G5Ac -FITC1.9-FA4.4 (Figure 1.6a, blue curve).  This 
evidence, coupled with strong quenching observed by G5Ac-COG-FA1.0, provides 
additional support for the conclusion that the multiple FAs present on G5Ac -FITC1.9-FA4.4 
do not generate additional FBP quenching, and therefore binding, and that the multiple FA 
ligands are not generating interactions with multiple proteins.  On the other hand, the FITC 
fluorescence increases upon addition of excess FA.  This suggests that G5Ac-FITC1.9-FA4.4 
is bound more weakly than G5Ac-COG-FA1.0 as it is displaced by excess FA. The Stern-
Volmers analysis of G5Ac -FITC1.9-FA4.4 showed this material quenches a similar fraction 
of accessible fluorophores (fa= 57 ± 2%) as compared to FA (fa = 67 ± 3%) with a slightly 
smaller dissociation constant of KD = 16.0 ± 1.9nM as opposed to KD = 27.9 ± 3.3nM from 
FA. 
The G5Ac-COG-FA1.0/FBP binding kinetics were studied under pseudo-first order 
conditions by mixing 1-20 nM G5Ac-COG-FA1.0 into a 58 nM FBP solution. The 
fluorescence changes were followed over 1-2 hours until equilibrium was reached (Figure 
1.7 inset).  The resulting curves were fit to single exponentials to obtain kobs for each 
concentration.  kobs was fit as a function of G5Ac-COG-FA1.0 concentration to the equation 
below that describes a two-step tight binding SOTB model. In the equation, we use P* to 
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indicate a change in protein structure, a common feature of the SOTB model, and L* to 
indicate the change in dendrimer structure as highlighted in Figure 1.1. 
 
 
2
2
[ ]
+
[ ]
obs
D
k L
k k
K L


 
The fit provided a KD value of 9.9  8.5 nM, a k2 value of 0.07  0.02 s-1, and a k-2 
value of 0.008  0.007 s-1 (Figure 1.7). Recall the KD value obtained from the modified 
Stern-Volmer analysis was 2.4 ± 0.2nM. These two values agree well with each other. The 
rate constant k2 indicates a slow onset binding interaction between the dendrimer and 
protein.  
Conclusions 
Substrate-triggered polymer 
binding to an FBP exosite gives an 
order of magnitude greater binding 
constant than that obtained by the 
native FA ligand. In addition, FA-
triggered exosite binding is not 
displaced by presence of a 28-fold 
excess of free FA. Tight polymer-
protein binding, triggered by specific 
P  +  L P-L P*-L*
k1 k2
k-1
k-2
Figure 1.7.  Binding kinetics between G5Ac-COG-FA1.0 and 
FBP.  kobs values were obtained by fitting the curves 
obtained for the addition of  1, 2, 5, 10, and 20 nm 
solution of G5Ac-COG-FA1.0 to 58 nM FBP (pH 7.4, 1x PBS 
solution). Inset: Change in fluorescence over time for 
addition of 2nM G5Ac-COG-FA1.0. 
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ligand binding, provides promising strategy for binding scaffolds containing drugs and/or 
imaging agents to desired protein targets. 
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Chapter II 
Nanoparticle Agglomeration Triggered by Protein Aggregation 
Introduction 
Folate receptor-targeted nanoparticles have been widely employed as a tumor 
targeting strategy for imaging and drug delivery applications.1-10 Conjugation of folic acid 
(FA) to small molecule drugs and nanoparticles provides a convenient, cheap, and 
chemically stable cancer targeting vector.  Despite substantial promise and seven clinical 
trials to date,11 neither molecular nor nanoparticulate FA conjugates have reached the clinic, 
suggesting challenges to their use in vivo. Herein, we focus on interactions of FA with 
serum folate binding protein (FBP) and how these interactions may impact the use of FA 
as a targeted delivery agent.   
It is well established that FA induces the aggregation of several proteins in serum, 
notably albumin, lactoferrin, and FBP.12-18 We have previously noted that FA-dendrimer 
conjugates can lead to strong binding interactions between the polymer and FBP surface19 
and that FA, methotrexate (MTX), and leucovorin all increase the aggregation propensity 
of FBP.18 Furthermore, FA- and MTX-polymer conjugates induce substantially more 
fluorescence quenching of FBP than FA or MTX alone, indicating that the conjugates are 
affecting protein structure and potentially aggregation behavior.20 For these reasons, we 
decided to explore the role of FA-induced FBP aggregation in causing the agglomeration 
of FA-conjugated nanoparticles. The formation of agglomerated particles and the masking 
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of the conjugated FA by FBP binding is likely to play an important role in transport and 
other in vivo behavior of FA-conjugated materials.  
For this initial study we selected the well-studied class of iron oxide particles (IOP) 
that have been explored for imaging and drug delivery applications.21-24  IOPs have been 
extensively investigated for imaging and drug delivery due to their low toxicity, 
biocompatibility, large surface area, and suitable magnetic properties. IOP-based agents in 
the 30 – 300 nm diameter size range have been approved for clinical use, and additional 
materials are currently in clinical trials.25 Particles under consideration have sizes ranging 
from 20 nm to 3500 nm in diameter.26 The majority of them are administered via 
intravenous injection. However, it is known that IOPs, especially unmodified ones, are 
prone to agglomeration and even precipitation in physiological environment.27 Therefore, 
investigation of IOP agglomeration in the presence of serum proteins is crucial when 
evaluating the safety and efficacy of these nanoparticles.  
Folic acid conjugated iron oxide nanoparticles were synthesized to study particle 
agglomeration in the presence of FBP and albumin (Figure 2.1). It was found that self-
aggregation of FBP upon FA binding further triggers the agglomeration of the IOP particles. 
Considering the drastically smaller size of protein compared to the iron oxide particles, this 
aggregation-agglomeration event resembles a biological cascade –  a small initial event 
(ligand-protein binding) leading to larger effects (protein structural rearrangement), that 
then leads to protein aggregation and particle agglomeration. The agglomerates formed are 
orders of magnitude larger in size than the initiating small molecule. Two iron oxide-FA 
conjugates, a ~40 nm FA-IOP and a ~450 nm FA-SeraMag, were selected for use in this 
study to model the range of particle sizes applied in the clinic. In particular, the ~40 nm 
18 
 
IOP represents a class of SPIONs (superparamagnetic iron oxide nanoparticles) that is a 
commonly used nanoparticle platform for drug conjugation and the development of 
targeted theranostics.28-30 The ~450 nm SeraMag is a commercially available particle 
widely used in protein separation and preparation.31-33 The two IOPs allow us to contrast 
the behavior of particles designed for very different applications, which highlights both 
different surface chemistry and size range. 
The FA-conjugated beads were mixed with human serum albumin (HSA) and folate 
binding protein (FBP) at the physiological concentration of these serum proteins. At 2 nM 
FBP with 0.01% w/w 40 nm particles in 1x PBS buffer (28 nM nominally), the cascade 
resulted in agglomeration to form 3800 ± 1100 nm diameter particles. Similarly, at 2 nM 
FBP with 0.01% w/w 450 nm particles (SeraMag) in 1x PBS buffer (16 pM nominally), 
agglomeration resulted in 4030 ± 1100 nm diameter particles. Albumin, the most abundant 
serum protein, had no significant impact on ~40 nm FA-IOP particle agglomeration up to 
the micromolar level; however, it did inhibit the agglomeration of the ~450 nm FA-
SeraMag particles. In addition to dynamic light scattering (DLS), atomic force microscopy 
(AFM) was carried out to study the morphology of agglomerated particles.  
Experimental Section 
Materials The ~450 nm amine-blocked iron oxide beads were obtained from GE 
healthcare (Sera-Mag SpeedBeads Amine-Blocked Particles, 10 mg/mL).  The ~40 nm iron 
oxide particles functionalized by polyethylene glycol(PEG-2k) with amine terminal groups 
were obtained from Ocean NanoTech. All other chemicals were purchased from Sigma 
Aldrich if not otherwise specified. The folate binding protein was isolated and purified as 
previously reported.2 
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Folic acid conjugation to magnetic beads 
Folic acid was conjugated to the beads via an EDC-NHS carbodiimide coupling 
procedure. Specifically, 300 L MilliQ water, 34 L folic acid solution (3.9 mg dissolved 
in 1 mL DMSO, then diluted 100x by MilliQ water), 51.7 L NHS solution (17.9 mg N-
Hydroxysuccinimide in 100 mL MilliQ water), 35.9 L EDC solution (4.0 mg 1-Ethyl-3-
(3-dimethylaminopropyl) carbodiimide in 100 mL MiliQ water) and 578.4 L MilliQ water 
were added into a vial for carboxylate activation. The vial was transferred to a shaker (23 
C, 115 rpm) for 7h (credit: Sarah Klem, Alexis K Jones).  
1% Magnetic bead stock solutions containing 0.05% sodium azide were vortexed 
and 1 mL was pipetted into a vial and placed on a magnet for about 3 min. The stock buffer 
was discarded and the beads washed with MilliQ water twice. The beads were re-suspended 
into the activation solution described above and allowed to react for 12 hrs.  The beads 
were then washed with water and characterized by IR spectroscopy. 
AFM experiment 
Protein solutions are made in filtered 1x PBS at their corresponding physiological 
concentration: 2 nM for FBP. The 1% conjugated beads stock solution was added into the 
protein solution to make a final concentration of 0.01% w/w. 40 L of the resulting solution 
was spin coated at 4,200 rpm onto a freshly cleaved mica surface. The sample was further 
rinsed with another 40 L milliQ water while spinning to rinse any remaining salt from the 
surface. PBS salts crystals can occasionally be found on the mica surface but they have 
dramatically different morphology from the IOP particles. AFM imaging was carried out 
in tapping mode using PicoPlus 5500 (Agilent Electronic Measurement, Aspire CT300R 
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tip) and NanoIR-2 (Anasys, Anasys PR-EX-T125-10 tip) AFM systems. For the ~ 40 nm 
FA-IOP the particle size is similar to the nominal 10 nm tip radius. Tip deconvolution was 
done to better estimate the particle diameter (d=dc
2/8R, where d is the particle diameter, dc 
is the observed diameter, and R is the tip radius).  
DLS experiment  
The sample solutions were prepared as describe for the AFM experiments. DLS 
was performed on a Nanosizer ZS (Malvern Instruments Ltd.) instrument.  The DLS in 
figure 2.2 and figure 2.4 was taken right after FBP addition into the solution. Additional 
DLS experiments on agglomerate particle stability were also taken under same conditions 
(Figures S7).  The solutions were measured in a 1 mL cuvette at 25 °C. The refractive index 
and absorption coefficient for the particles were set at 2.42 and 0.01, respectively. All data 
is an average of 15 scans. 
Results and Discussion 
Folic acid modification on IOP surfaces has widely been used as a targeting strategy 
in drug development. The surface modification of folic acid on IOP may influence the 
interactions of the particles with serum proteins in a nonspecific fashion due to its 
 
Figure 2.1. A target-ligand triggered biological cascade.  Addition of a physiological concentration of 
folate binding protein (2 nM FBP) triggers the agglomeration of the large folic acid conjugated iron 
oxide particles in 1x PBS, even with the presence of a high concentration of human serum albumin. 
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hydrophobicity and in a specific fashion due to FA-FBP interactions.  Both of these 
interactions have the potential to lead to particle agglomeration in the blood serum.  
FBP and albumin are the proteins primarily responsible for the binding and 
transportation of folates in blood serum.34 FBP exists at a 1-2 nM concentration in human 
serum whereas the much more abundant human serum albumin (HSA) is present at 30 
μM.35 FBP binds to FA tightly with a nanomolar dissociation constant, and the protein self-
aggregates upon substrate binding.2, 14 Crystallographic studies indicate that FBP forms a 
beta sheet upon folic acid binding and it is hypothesized that this contributes to the 
aggregation of the protein. 20 This observation led us to wonder if the protein-protein 
aggregation could also trigger the agglomeration of large FA conjugated particles. FBP 
aggregation is stable at pH 6-9 and at temperatures ranging from 20°C to 37°C.16, 36 HSA 
is a ~40,000 times weaker binder for folate as compared to FBP.37 However, it composes 
more than half of total serum proteins and is also involved in folate transportation and 
regulation in blood. 
 
Figure 2.2. Agglomeration of ~40 nm FA-IOP triggered by FBP binding and aggregation as measured by 
DLS: a) 0.01% w/w FA-IOP + 2 nM FBP followed by addition of HSA. b) 0.01% w/w FA-IOP + HSA 
followed by addition of 2 nM FBP. 
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  In this study, two iron oxide particles are coated with FA via EDC/NHS coupling 
as a model system for folic acid-targeted nanomedicine. The particles were characterized 
using infrared spectroscopy. The ~40 nm FA-IOP IR spectrum has peaks at 2916 cm-1 and 
2851 cm-1, which correspond to the CH2 stretching vibrations for the polyethyleneglycol 
(PEG) surface coating on iron oxide nanoparticles.38 An FA carbonyl stretch, 1646 cm-1  
for free FA, is observed at 1632 cm-1 for conjugated FA-IOP. A strong peak at 983 cm-1 is 
also indicative of FA and shifts to 1004 cm-1 upon conjugation. The FA-SeraMag showed 
a peak at 1560 cm-1 in the IR spectrum, which is also detected in the unconjugated SeraMag 
IR spectrum. An FA carbonyl stretch appears at 1654 cm-1 in the conjugated particle and 
appears to provide an increase in intensity in that region.  A strong peak at 989 cm-1 is also 
observed for conjugated material. 
DLS and AFM were employed to study the agglomeration of particles induced by 
serum protein binding. A 0.01% w/w FA- conjugated nanoparticle (FA-IOP and FA-
SeraMag) solution was mixed with serum proteins at their physiological concentration. All 
the solutions were made in 1x PBS buffer to mimic the salt environment in blood serum. 
The 0.01% w/w (28 nM nominally) ~40 nm FA-IOP aqueous 1X PBS solution yielded one 
peak with a number weighted average diameter at 39 ± 13 nm (Figure 2.2a). Upon mixing 
with 2 nM FBP, a peak centered at 3800 ± 1100 nm was detected. The resulting 
agglomerate is nearly 100-fold larger in diameter (106 larger in volume) than the original 
particle. Addition of up to 6 µM HSA into this solution did not have a significant impact 
on the DLS signal. This process was also studied in reverse: HSA was added to the FA-
IOP solution prior to FBP addition. At 30 µM HSA, the particles have a measured diameter 
of 42 ± 13 nm (Figure 2.2b). The hydrodynamic size of HSA monomer is also detected 
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under this condition at 7.0 ± 1.4 nm, which is in agreement with the literature value.39, 40 
These data indicate the HSA non-specific binding on this particle is minimal. Addition of 
2 nM FBP into this FA-IOP/HSA solution generated agglomerated particles with a 
diameter of 3100 ± 850 nm, and zeta potential of 4.7 ± 0.3mV. These data indicate that 
HSA does not trigger a cascade and that excess HSA does not inhibit particle 
agglomeration upon the addition of FBP. 
In order to obtain information about particle morphology, the solutions were spin 
coated onto a cleaved mica surface and characterized using tapping mode AFM (Figure 
2.3). The 0.01% w/w FA-IOP particles alone demonstrated a well-dispersed non-
agglomerated pattern on the mica surface with an average diameter of 59 ± 7 nm (Figure 
 
Figure 2.3. AFM image of the ~40 nm FA-IOP mixed with FBP. a) 0.01% w/w FA-IOP without FBP b) A 
typical agglomerated particle at 0.01% w/w FA-IOP + 2 nM FBP c) Line scan profile of the 
agglomerated particles. The particle surface can be sectioned into ~50 nm spheres d) 3D rendering of 
an agglomerated particle.  
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2.3a).  This diameter was corrected to 44 ± 10 nm after tip deconvolution. FBP-assisted 
particle agglomeration was observed by AFM once the 0.01% w/w FA-IOP particle was 
mixed with 2 nM FBP. An average of five agglomerates yielded a particle volume of 58 ± 
1.9 μm3 (equivalent to ~210,000 ~40 nm FA-IOP particles), corresponding to an average 
diameter of ~ 2400 ± 800 nm. The particle diameter falls into the size range measured by 
DLS (Figure 2.3b). The large particle agglomerates featured a rough surface consisting of 
distinct particles and line scan profiles demonstrated the existence of ~50 nm particles on 
the agglomerate surface (Figure 2.3c). The size of the smaller components in the line scan 
is consistent with the size of individual FA-IOP particles. A 3D rendering of the aggregated 
particle is illustrated in Figure 2.3d. The small FA-IOP particles on the surface can be 
easily seen in the large agglomerated particle. For the HSA containing samples, the high 
HSA concentration resulted in a multi-layer protein coating on the mica surface and this 
prevented measurement of the IOP aggregates. 
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The much larger FA-SeraMag particle (450 ± 70nm) was also titrated with FBP and 
HSA under similar conditions (Figure 2.4a). The addition of 2 nM FBP to form a 0.01% 
w/w solution (16 pM nominally) shifted the entire peak to 4030 ± 1100 nm with a measured 
zeta potential of 1.5 ± 0.2 mV. The original peak for the 450 nm particles was no longer 
observable. This indicates a full agglomeration of particles in the presence of 2 nM FBP. 
This full shift of the peak is most likely due to the much higher protein to particle molarity 
ratio in this case. For each ~450 nm FA-SeraMag particle there were 125 FBP protein 
added whereas for each ~40 nm FA-IOP there were just 0.07 FBP (i.e., 14 IOP per FBP). 
On the other hand, 600 µM (40 g/L) HSA lead to a two-fold increase in diameter (880 ± 
360 nm). This could be due to nonspecific binding from HSA and formation of a protein 
 
Figure 2.4. a) Agglomeration of the ~450 nm FA-IOP triggered by FBP binding and aggregation as 
measured by DLS. b) AFM image of 0.01% w/w FA-SeraMag mixed with 2nM FBP. c) Line scan profile 
of the agglomerated particles. The particle surface is composed of ~500nm spheres d) 3D image of the 
agglomerated particles.  
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corona at this concentration. Addition of 2 nM FBP into this solution did not introduce a 
full shift of this ~880 nm particle to a large agglomeration as was the case without HSA. 
However, the peak associated with the ~880 nm particle exhibits tailing (Figure 2.4a, pink) 
up to a diameter of ~3200 nm. It is worth noting that in the presence of HSA only a small 
fraction of FA-SeraMag particles shifted to the large agglomeration and this differs 
substantially from  the addition of FBP alone. This leads us to hypothesize that the HSA 
protein corona could be protecting the FA-SeraMag particles from agglomeration. The FBP 
assisted particle agglomeration was measured by AFM for solutions containing 0.01% w/w 
FA-SeraMag particle mixed with 2 nM FBP (Figures 4b, S5). The large agglomerate 
featured a rough surface and the line scan profile demonstrated the existence of ~500 nm 
particles (Figure 2.4c). This result indicates that the large particle agglomerate is composed 
of the smaller FA-SeraMag components. A 3D rendering of the agglomerated particle is 
also shown in Figure 2.4d. In this case, the average agglomerate contains ~360 FA-
SeraMag particles. A summary of DLS size measurement for both IOPs is provided in 
Table I.  
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The FBP-induced agglomeration of the ~40 nm and ~450 nm IOP resembles a 
biological cascade in two ways.  First, there are three discrete steps (ligand binding, protein 
structural change, protein self-aggregation) preceding the fourth step (particle 
agglomeration). Second, the initial interaction occurs on a small scale (small molecule 
interaction with the protein binding pocket).  This small interaction triggers a series of 
changes that results in agglomeration of the much larger ~40 nm and ~450 nm IOP. 
Under the physiological concentrations employed, HSA is in large excess to the 
IOPs. However, HSA does not bind to FA as tightly as FBP. The combination of these two 
factors results in a substantial amount of free HSA left in solution. The non-specific binding 
Table I. Number weighted average particle diameter from DLS 
Sample  # weighted average 
Ave. Dia. Peak 1 
/nm 
# weighted average 
Ave. Dia. Peak 2 
/nm 
# weighted 
average Dia. Peak 
3 /nm 
0.01% w/w FA-IOP - 39 ± 13  - 
0.01% w/w FA-IOP 
+ 2nM FBP 
- 39 ± 13 3800 ± 1100 
0.01% w/w FA-IOP 
+ 30 µM HSA 
7.3 ± 1.5 42 ± 13 - 
0.01% w/w FA-IOP 
+ 30 µM HSA+ 2nM 
FBP 
7.0 ± 1.4 54 ± 10 3100 ± 850 
0.01% w/w FA-
SeraMag 
- 450 ± 70 - 
0.01% w/w FA-
SeraMag  
+ 2nM FBP 
- - 4030 ± 1100 
0.01% w/w FA-
SeraMag  
+ 600µM HSA 
6.4 ± 1.0 880 ± 360 - 
0.01% w/w FA-
SeraMag  
+ 600µM HSA+ 2nM 
FBP 
6.3 ± 0.9 840 ± 330 - 
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of HSA to the surface conjugated FA does not introduce a structural change in HSA that 
can induce IOP agglomeration.  However, addition of 2 nM FBP into the ~40 nm IOP-
HSA solution does generate particle agglomeration. This shows that physiological 
concentrations of FBP trigger can particle agglomeration even in the presence of the large 
concentration of HSA found physiologically. HSA on the particle may make the surface 
less accessible to FBP and provide some protection to IOP particle from agglomeration and 
this is observed for the ~450 nm IOP where there is a much higher HSA concentration per 
particle.41  
Particle size can have a significant impact on tissue distribution in vivo. Particles 
larger than 2000 nm accumulate readily in the spleen and liver. Particles ranging from 100 
nm and 200 nm have been shown to escape liver and spleen filtration, while small 
nanoparticles are filtered out by the kidneys.42 For the iron oxide particles in this study, 
physiological concentrations of FBP triggered the agglomeration of FA-IOP in the 
presence of HSA and altered them from ~ 40 nm diameter particles that could readily 
transport through tissue into ~3000-4000 nm diameter particles that would be incapable of 
tissue penetration and would be trafficked to spleen and liver. The result illustrates the 
importance of considering serum protein-induced particle agglomeration when designing 
FA-targeted systems. 
Conclusion 
Nano-engineered drug delivery platforms have received great attention in the past 
decade as therapeutic and diagnostic tools.3, 43-49 In order to best understand the safety and 
efficacy of these targeted nanomaterials in vivo, previous studies have explored the 
interactions with serum proteins.41, 50-52 It is widely proposed that the absorbed protein layer 
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on nanomaterials influences the bio-identity and therein the transportation and uptake of 
the nanomaterial into target cells.53-56 Future in vitro studies of the nanomaterial interaction 
with serum proteins, and the resulting effect on cellular uptake, will play an essential role 
in understanding the pathology of these materials. In the work described here, folic acid-
conjugated iron oxide nanoparticles, initiate a set of interactions with serum proteins that 
leads to particle agglomeration. Additional work is needed to fully understand the 
implications of this agglomeration for biological trafficking and potential health risks.57-63  
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Chapter III. 
Multi-scale Anterior Cruciate Ligament Microdamage due to Normal Mechanical 
Loading 
Introduction 
The anterior cruciate ligament (ACL) is a key connective tissue stabilizing the knee. 
Over 200,000 ACL injuries occur annually in the US1. The lifetime public health burden 
of ACL tears in the US was estimated to be $7.6 billion annually when treated with 
reconstruction and $17.7 billion annually when treated with rehabilitation.1 The number of 
ACL reconstructions in the US is growing rapidly with an estimated annual increase 
between 3.4% and 7.7%.2-4 Among them, nearly three quarters of ACL injuries follow a 
non-contact mechanism even in the high contact sport of NFL football.5 However, the 
cause of non-contact ACL injuries remains somewhat of an enigma. Several theories have 
been proposed to explain the mechanism of non-contact ACL injury, including aggressive 
quadriceps loading,6 excessive joint compressive loading,7 awkward landing or 
decelerating gestures,8  and neuromuscular control deficit.9  
Current orthopedic studies focus mainly on the acute triggers of the injury, per the 
traditional view of the non-contact ACL injury. Very few studies have been conducted to 
explore the development of pre-injury ACL damage under repetitive loading. In this study, 
we ask one key question: What level of damage, if any, would the human ACL sustain 
under routine mechanical loading?  If the knee joint experiences 2-3 times body weight 
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during normal walking10 and 3-4.5 times body weight during light sport activities such as 
jogging, golf and tennis.11, 12 In previous studies, Wojtys et al have demonstrated in vitro 
that the ACL could experience fatigue failure in fewer than 100 repeated landings with 
limited internal femoral rotation.13 The characterization of ACL damage from those 
loading tests is the major focus of this paper. 
In this study, the ACL microdamage produced in cadaveric knees was visualized 
and evaluated at multiple levels from molecular, fibril, and tissue levels. Molecular level 
ACL damage was investigated using both IR spectroscopy and fluorescent collagen 
hybridizing peptide (CHP) probes. In the IR spectroscopy, an amide I peak shift from 1664 
cm-1 to 1740 cm-1 is closely associated with ligament collagen damage. The TAMRA dye 
conjugated fluorescent CHP probe can detect the molecular level unwinding of collagen 
after mechanical testing.14 Fibril level collagen damage was investigated using atomic 
force microscopy (AFM). Fibril voids at nanometer scale ranging from 10 nm to 100 nm 
were observed after mechanical testing. Tissue level collagen damage was studied using 
second harmonic generation. The mechanically tested tissue demonstrated larger fibril 
voids compared to the untested control. Only one knee tested in this study led to complete 
mechanical failure after loading but they all demonstrated different levels of microdamage 
across all scales. 
The combination of these techniques allowed systematic investigation of the ACL 
microdamage under repeated loading. This microdamage helps deepen the understanding 
of process of pre-fracture ACL fatigue.  Eventually this understanding would help guide 
the development, preventive training and treatment plans for athletes and active people. 
Experimental Section 
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ACL sample preparation 
The cadaveric knees are tested on a custom-built apparatus to simulate repeated 
single-leg pivot landings as described in previous report.15 One knee from each pair was 
set aside as an internal control. After mechanical testing, the ACL explant was extracted 
and cut in half longitudinally. Each half was embedded in a water-soluble mounting 
medium SCEM (Super Cryo Embedding Medium, Section Lab). The embedded tissues 
(both tested and control) were sectioned using a tungsten carbide blade (Leica, #TC-65) 
under -25 ℃ (Leica cryostat model 3050S, 8°, 20 μm).  The sectioned tissue was 
transferred to adhesive tapes using the Kowamoto method.16, 17 The sectioned sample slices 
were stored in a moisturized chamber under -20℃ until being imaged. 
AFM-IR data collection  
The sectioned sample slices were immersed in deionized water to remove the 
embedding media and keep the sample hydrolyzed. The tape containing the ACL enthesis 
was cut to a ~2cm square and glued to a stainless-steel AFM sample puck. The AFM-IR 
data was collected using a NanoIR2 system (Anasys Instruments). For a typical IR map, 
the images are taken at 2*2 μm2, co-average 256x, power 2.07% and trace speed 0.1Hz.  
SHG and fluorescence data collection  
The samples are stained with a CHP-TAMRA dye after the AFM-IR imaging. The 
peptide sequence can be found from the previous publication.14 The peptide was 
synthesized by Pierce Custom Peptides. The TAMRA fluorophore was picked so the 
fluorescence is not overlapping with the sample autofluorescence or the SHG signal. 
Before peptide staining, 25 μL CHP stock solution (150 μM) was heated under 80 ℃ for 
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10min to deaggregate the peptide. The solution was quenched by immersion in 4 ℃ water 
for 15 seconds. The aliquot was diluted to a total volume of 500 μL and dropped onto the 
ACL slice. The sample was incubated in dark in a 4 ℃ fridge overnight. The sample was 
rinsed with 1mL PBS three times before immersed in oil (Leica type F) for microscopic 
imaging. The images are collected using a Leica SP8 confocal microscopy system. The 
light source was a 910nm IR laser (10% LP, 33% gain, 38% offset, pinhole wide open). 
Two PMT detectors are set at 440nm for the detection of SHG forward/backward signal. 
The fluorescence signal was detected at a 570-590 nm window.  
Results and Discussion  
Fibril damage detected by AFM-IR 
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 Atomic force microscopy is a common tool of studying the collagen order and 
morphology at nano meter scale. The AFM images from the 
failed patient ACL and the mechanically tested cadaveric ACL 
were compared (figure 3.1). This data showed fibril voids 
ranging from 20 nm to 150 nm on both types of tissues. The 
fibril voids appear as the dark spheres on the AFM images. The 
fibril voids sizes are very similar between the case of the failed 
patient ACL and the mechanically tested cadaver ACL. These 
sphere patterns were not observed on the untested cadaveric 
control. The size range of those fibril voids falls into the size 
range for collagen fibrils. It is possible that individual collagen 
fibril on the ligament was pulled out during the mechanical 
testing and subsequently leaving the fibril voids on the 
ligament.  
Figure. 3.1. AFM height 
images of voids in 
ligament associated with 
mechanically induced 
microdamage. A) Failed 
patient ACL, B) 
Mechanically tested 
cadaver ACL.   
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Additionally, on the AFM-IR system, an 
enhanced 1740 cm-1 peak was detected on the 
spectrum of the mechanically tested sample (figure 
3.2). This peak is shifted from the collagen amide I 
peak at 1660 cm-1 and this 1740 cm-1 peak can also 
be reversibly created by dehydrating/rehydrating the 
collagen tissue. This disordered collagen peak can 
also be observed on the fractured patient ACL and 
is not present on the untested cadaveric ACL control. 
This IR peak demonstrated the microdamage on the 
ACL could be deeper into the molecular level and at 
a scale even smaller than the fibril level damage as 
detected by the AFM technique. This peak is indicating the unwinding of the collagen fibril 
is happening when the ACL was mechanically tested under submaximal loading.  
Figure. 3.2. AFM-IR spectra from the 
ligament of A) explant from 
mechanically tested cadaveric ACL, B) 
explant from patient having failed 
ACL, C) explanted of untested 
cadaveric ACL. 
 
 
 
Figure 3.3. fibril void on ligament detected by SHG. 
Untested
3x body weight, 100 cycles
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Fibril damage detected by SHG and confocal microscopy  
 Collagen molecules are well aligned biopolymers and can be specifically detected 
by second harmonic generation. SHG imaging showed fibril voids at the micrometer scale 
(figure 3.3). The tested ACL demonstrated the spherical fibril voids. Fibril void analysis 
on the sectioned ACL showed that the collagen SHG fibril voids on the tested ACL is 
approximately ten times larger than the control ACL (figure 3.3 right). Additionally, the 
samples are incubated with TAMRA conjugated collagen hybrid peptide (CHP) to detect 
the molecular level damage. The CHP has a complementary sequence to the collagen and 
can bind specifically to the unwound collagen molecules. The conjugated TAMRA dye on 
the peptide has a red fluorescence that is away from the autofluorescence and the TAMRA 
intensity could be the indication of molecular level collagen damage. The tested ACL 
sample demonstrated an increased TAMRA fluorescence hence higher CHP binding 
 
Figure 3.4. collagen disordering detected by CHP-TAMRA. 
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towards the ACL (figure 3.4). This is consistent with the IR data demonstrating the 
molecular level damage of the ACL after the mechanical testing. 
Conclusion 
This study demonstrated the evidence of the hierarchical ACL damages at different scales 
after the mechanical testing. The fibril and fiber voids observed on AFM and SHG 
resembles the voids observed on fractured ACL. These results support the hypothesis that 
the microdamages can result from normal mechanical loading and eventually become a 
risk factor for ACL injuries.  More cadaveric data and the comparison between the cadaver 
and patient could help develop further understanding of the non-contact ACL damages.  
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Conclusions and Future Directions 
The substrate-triggered polymer binding to an FBP exosite provides a new protein 
binding strategy. The polymer scaffold can not only act as the drug delivery vector, but 
also the booster for protein binding affinities. This design strategy may not be limited to 
the design to FBP binders. This strategy could save a lot resources in the new drug design 
and be resistant to single site protein mutation. The protein surface and polymer surface 
interaction may be the most important factor to consider in such design. The FBP triggered 
nanoparticle agglomeration could pose a risk factor in the targeted drug development. How 
these nanoparticles interact with other serum proteins, and the lipid in the blood serum, 
would be the next question to answer. These works could help further understand the 
implications of this agglomeration for biological trafficking and potential health risks. 
For the ACL project, the evidence has been accumulating that the microdamage to 
the ACL occurs after the mechanical loading at the ACL without the presence of ACL 
fracture. The next step is to understand how the ACL fractures develop overtime when 
people age and ACL become repetitively loaded. A diagnostic tool, such as a SHG or 
fluorescence endoscope, can be developed to help the clinicians to better illustrate the 
development of the ACL injury. These tools could also help the improvement of exercising 
and training practices to better protect the ACL of athletes or common people. 
